DOCSLIB.ORG

Myeloma Patients MMSET Survival Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Myeloma Patients MMSET Survival Of Published OnlineFirst February 4, 2016; DOI: 10.1158/1078-0432.CCR-15-2366 Personalized Medicine and Imaging Clinical Cancer Research Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients S. Peter Wu1, Ruth M. Pfeiffer2, Inhye E. Ahn1, Sham Mailankody3, Pieter Sonneveld4, Mark van Duin4, Nikhil C. Munshi5, Brian A. Walker6, Gareth Morgan7, and Ola Landgren3 Abstract Purpose: The poor prognosis of multiple myeloma with Results: Ten MMSET-like probes were associated with poor t(4;14) is driven by the fusion of genes encoding multiple mye- survival in non-MMSET myeloma. Non-MMSET myeloma loma SET domain (MMSET) and immunoglobulin heavy chain. patients in the highest quartile of the 10-gene signature Specific genes affected by MMSET and their clinical implications (MMSET-like myeloma) had 5-year overall survival similar to in non-MMSET myeloma remain undetermined. that of MMSET myeloma [highest quartile vs. lowest quartile HR Experimental Design: We obtained gene expression profiles of ¼ 2.0; 95% confidence interval (CI), 1.5–2.8 in MMSET-like 1,032 newly diagnosed myeloma patients enrolled in Total Ther- myeloma; HR ¼ 2.3; 95% CI, 1.6–3.3 in MMSET myeloma]. apy 2, Total Therapy 3, Myeloma IX, and HOVON65-GMMGHD4 Analyses of MMSET-like gene signature suggested the involve- trials and 156 patients from Multiple Myeloma Resource Collec- ment of p53 and MYC pathways. tion. Probes that correlated most with MMSET myeloma were Conclusions: MMSET-like gene signature captures a subset of selected on the basis of a multivariable linear regression and high-risk myeloma patients underrepresented by conventional Bonferroni correction and refined on the basis of the strength of risk stratification platforms and defines a distinct biologic sub- association with survival in non-MMSET patients. type. Clin Cancer Res; 22(16); 4039–44. Ó2016 AACR. Introduction histone methyltransferase, its overexpression has been attributed to alter epigenetic regulation of genes involved in cell-cycle Multiple myeloma has extremely heterogeneous outcomes. progression and DNA damage repair (7). However, downstream Among many prognostic factors utilized in myeloma, transloca- gene targets and molecular pathways regulated by MMSET remain tion t(4;14)(p16.3;q32.3) is an oncogenic event associated with unclear. poor prognosis (1). The key molecular target of t(4;14) is multiple What is also unknown in myeloma is the presence of biologic myeloma SET domain (MMSET) at chromosomal band 4p16.3 homology shared between high-risk and non–high-risk sub- (2–5). The detection of MMSET overexpression with gene expres- groups. This question comes within the context of the recent sion profiling (GEP) consistently identifies a high-risk subgroup advancement of genetic sequencing, which identified diverse in multiple myeloma (6). Although the prognostic significance of spectrum of disease biology that, at times, redefined conventional MMSET is well established, the underlying mechanism of its risk stratification and management. For instance, "BRCA-ness" excess risk is poorly understood. Given that MMSET encodes was identified in up to 14% of non–small cell lung cancer and 15% of head and neck cancer patients due to epigenetic inacti- vation of genes responsible for DNA damage repair, such as 1Multiple Myeloma Section, NCI, NIH, Bethesda, Maryland. 2Depart- BRCA1 and FNACF (8). In breast and ovarian cancers, next- ment of Cancer Epidemiology and Genetics, Biostatistics Branch, NCI, NIH, Rockville, Maryland. 3Myeloma Service, Memorial Sloan Kettering generation sequencing demonstrating the presence of certain Cancer Center, New York, New York. 4Department of Hematology, genes beyond BRCA1/2, such as PALB2, ATM,orCHEK2, was Erasmus University Medical Center, Rotterdam, the Netherlands. strongly associated with an increased risk of cancer diagnosis and 5 Lebow Institute of Myeloma Therapeutics and Jerome Lipper Multi- early death (9–11). Recent discoveries in solid tumor suggest a ple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 6Section of Haemato-Oncology, The substantial proportion of cancer patients harbor molecular sig- Institute of Cancer Research, London, United Kingdom. 7Myeloma natures similar to those of high-risk subtypes. Institute for Research and Therapy, University of Arkansas for Medical We hypothesize there is an overlap of disease biology between Sciences, Little Rock, Arkansas. the established high-risk myeloma and its non–high-risk coun- Note: Supplementary data for this article are available at Clinical Cancer terpart. Specifically, the same genes involved in the pathogenesis Research Online (http://clincancerres.aacrjournals.org/). and adverse outcomes of MMSET myeloma (6) could also be Corresponding Author: Ola Landgren, Memorial Sloan Kettering Cancer Center, relevant to a subset of non-MMSET patients with poor clinical 1275 York Avenue, New York, NY 10065. Phone: 212-639-5126; Fax: 646-227- outcomes (hereby referred to as "MMSET-like myeloma"). To 7116; E-mail: [email protected] characterize genes and molecular pathways influencing survival doi: 10.1158/1078-0432.CCR-15-2366 across different myeloma subtypes, we assessed expression levels Ó2016 American Association for Cancer Research. of 54,675 genes in 1,188 newly diagnosed multiple myeloma www.aacrjournals.org 4039 Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2016 American Association for Cancer Research. Published OnlineFirst February 4, 2016; DOI: 10.1158/1078-0432.CCR-15-2366 Wu et al. Translational Relevance Materials and Methods Study design Multiple myeloma is a biologically and clinically heteroge- From the NCBI Gene Expression Omnibus (GEO), we down- neous disease. The presence of biologic homology shared loaded unprocessed CEL files from the following datasets: Total between conventional high-risk and non–high-risk myeloma Therapy (TT) 2 (N ¼ 345, accession number GSE2658, subgroups has not been reported to date. We hypothesized NCT00083551); TT 3 (N ¼ 214, accession number GSE2658, that molecular risk stratification can capture biologic homol- NCT00081939); HOVON65/GMMG-HD4, (N ¼ 320, accession ogy between patients with or without multiple myeloma SET number GSE19784, ISRCTN64455289); Myeloma IX (N ¼ 247, domain (MMSET) overexpression and be used as a prognostic accession number GSE15695, ISRCTN68454111); and Multiple tool. We identified 10-gene signature associated with MMSET Myeloma Resource Collection (MMRC; N ¼ 288, accession number myeloma. We obtained gene expression profiles of 1,032 GSE26760). The sample size of each dataset was determined after newly diagnosed myeloma patients enrolled in Total Therapy excluding 8 profiles (accession number GSE19784) that were nor- 2, Total Therapy 3, Myeloma IX, and HOVON65-GMMGHD4 mal plasma cells and 16 patients (accession number GSE26760) trials and 156 patients from Multiple Myeloma Resource who were smoldering myeloma (n ¼ 11), MGUS (n ¼ 2), or plasma Collection. Expression of MMSET-like gene signature in cell leukemia (n ¼ 3). Anonymized patient characteristics of TT trials non-MMSET subgroup was associated with similarly poor were obtained from GEO and were identified with the same acces- survival. Pathway analysis of MMSET-like gene signature sion numbers. Anonymized patient characteristics of Myeloma IX revealed the involvement of p53 and MYC signaling pathways. and HOVON65/GMMG-HD4 trials were obtained through person- MMSET-like gene signature captures a subset of high-risk al correspondence with M. van Duin and Ping Wu (Section of myeloma patients underrepresented by conventional risk Haemato-Oncology, The Institute of Cancer Research, London, UK), stratification platforms and defines a distinct biologic subtype. respectively. Anonymized patient characteristics of MMRC were obtained from Multiple Myeloma Genome Portal (12). Selected characteristics of patients from the five studies are shown in Table 1. þ All gene expression data were derived from CD138 purified patients. Among 71 genes significantly altered in MMSET mye- plasma cells of newly diagnosed myeloma patients, which were loma, 10 genes most strongly associated with survival were hybridized to Affymetrix Human Genome U133 Plus 2.0 cDNA selected and combined into a GEP risk score. Patients who did microarray. All raw CEL files were processed using the justMAS not have detectable MMSET but were at the top quartile of the 10- function in the R statistical programming language, and gene gene risk score were categorized as MMSET-like myeloma. Five- expression levels were log2 transformed. The final dataset included year survivals were similar between patients with MMSET mye- GEPs of 1,188 myeloma patients with complete data for age, sex, loma and MMSET-like myeloma. Pathway analysis identified b2-microglobulin, and albumin. For the HOVON65/GMMG-HD4 MYC and TP53 transcriptional regulators as lead candidates trial, FISH data regarding MMSET status were available for 241 targeted by the observed genes within the risk score. Our findings patients; MMSET status by FISH versus gene expression revealed a suggest there is a homology of aggressive disease biology and correlation of 0.81 (Spearman r). For the analysis of survival clinical outcomes shared between MMSET myeloma and a subset outcomes, we excluded 156 patients from MMRC, as it was not a of non-MMSET myeloma. clinical trial, and only used the remaining data from 1,032 patients. Table 1. Patient and study characteristics Median age, Women,
Load more

Recommended publications
  • Supplementary Information
    Supplementary Information This text file includes: Supplementary Methods Supplementary Figure 1-13, 15-30 Supplementary Table 1-8, 16, 20-21, 23, 25-37, 40-41 1 1. Samples, DNA extraction and genome sequencing 1.1 Ethical statements and sample storage The ethical statements of collecting and processing tissue samples for each species are listed as follows: Myotis myotis: All procedures were carried out in accordance with the ethical guidelines and permits (AREC-13-38-Teeling) delivered by the University College Dublin and the Préfet du Morbihan, awarded to Emma Teeling and Sébastien Puechmaille respectively. A single M. myotis individual was humanely sacrificed given that she had lethal injuries, and dissected. Rhinolophus ferrumequinum: All the procedures were conducted under the license (Natural England 2016-25216-SCI-SCI) issued to Gareth Jones. The individual bat died unexpectedly and suddenly during sampling and was dissected immediately. Pipistrellus kuhlii: The sampling procedure was carried out following all the applicable national guidelines for the care and use of animals. Sampling was done in accordance with all the relevant wildlife legislation and approved by the Ministry of Environment (Ministero della Tutela del Territorio e del Mare, Aut.Prot. N˚: 13040, 26/03/2014). Molossus molossus: All sampling methods were approved by the Ministerio de Ambiente de Panamá (SE/A-29-18) and by the Institutional Animal Care and Use Committee of the Smithsonian Tropical Research Institute (2017-0815-2020). Phyllostomus discolor: P. discolor bats originated from a breeding colony in the Department Biology II of the Ludwig-Maximilians-University in Munich. Approval to keep and breed the bats was issued by the Munich district veterinary office.
    [Show full text]
  • Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition 12-19-2010 Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P. Stewart Marshall University Hyoung Y. Kim University of Tennessee - Knoxville, [email protected] Arnold M. Saxton University of Tennessee - Knoxville, [email protected] Jung H. Kim Marshall University Follow this and additional works at: https://trace.tennessee.edu/utk_nutrpubs Part of the Animal Sciences Commons, and the Nutrition Commons Recommended Citation BMC Genomics 2010, 11:713 doi:10.1186/1471-2164-11-713 This Article is brought to you for free and open access by the Nutrition at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Nutrition Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Stewart et al. BMC Genomics 2010, 11:713 http://www.biomedcentral.com/1471-2164/11/713 RESEARCH ARTICLE Open Access Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P Stewart1, Hyoung Yon Kim2, Arnold M Saxton3, Jung Han Kim1* Abstract Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/ JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia.
    [Show full text]
  • Long Non-Coding RNA00844 Inhibits MAPK Signaling to Suppress the Progression of Hepatocellular Carcinoma by Targeting AZGP1
    1 Original Article Page 1 of 15 Long non-coding RNA00844 inhibits MAPK signaling to suppress the progression of hepatocellular carcinoma by targeting AZGP1 Bingyi Lin1,2#, Hui He2#, Qijun Zhang2, Jie Zhang3, Liu Xu3, Lin Zhou1,2, Shusen Zheng1,2, Liming Wu1 1Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; 2Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Hangzhou, China; 3Department of Hepatobiliary Surgery, First Hospital of Jiaxing, Jiaxing University, China Contributions: (I) Conception and design: L Wu, S Zheng; (II) Administrative support: L Wu, S Zheng; (III) Provision of study materials or patients: B Lin, H He; (IV) Collection and assembly of data: L Xu, L Zhou; (V) Data analysis and interpretation: Q Zhang, J Zhang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Liming Wu; Shusen Zheng. Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, China. Email: [email protected]; [email protected]. Background: Previous data have confirmed that disordered long non-coding ribonucleic acid (lncRNA) expression is evident in many cancers and is correlated with tumor progression. The present study aimed to investigate the function of long non-coding RNA00844 (LINC00844) in hepatocellular carcinoma (HCC). Methods: The expression levels of target genes were detected with real-time polymerase chain reaction (PCR) and western blotting. The biologic function of HCC cells was determined with cell viability assay, colony formation assay, cell cycle analysis, apoptosis detection, and Transwell migration assay in vitro.
    [Show full text]
  • Gene-Expression Signatures of Nasal Polyps Associated with Chronic
    Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma Michael Platta, Ralph Metsonb and Konstantina Stankovicb,c,d aDepartment of Otolaryngology, Head and Neck Purpose of review Surgery, Boston University, bDepartment of Otology and Laryngology, Harvard Medical School, The purpose of this review is to highlight recent advances in gene-expression profiling of cDepartment of Otolaryngology and dEaton Peabody nasal polyps in patients with chronic rhinosinusitis and aspirin-sensitive asthma. Laboratory, Massachusetts Eye and Ear Infirmary, Recent findings Boston, Massachusetts, USA Gene-expression profiling has allowed simultaneous interrogation of thousands of genes, Correspondence to Konstantina Stankovic, MD, PhD, Massachusetts Eye and Ear Infirmary, 243 Charles St., including the entire genome, to better understand distinct biological and clinical Boston, MA 02114, USA phenotypes associated with nasal polyps. The genes with altered expression in nasal Tel: +1 617 523 7900; e-mail: [email protected] polyps are involved in many cellular processes, including growth and development, immune functions, and signal transduction. The wide-ranging and typically Current Opinion in Allergy and Clinical Immunology 2009, 9:23–28 nonoverlapping results reported in the published studies reflect methodological and demographic differences. The identified genes present possible novel therapeutic targets for nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma.
    [Show full text]
  • Weighted Gene Expression Profiles Identify Diagnostic and Prognostic
    Validation Study Journal of International Medical Research 48(3) 1–12 Weighted gene expression ! The Author(s) 2019 Article reuse guidelines: profiles identify diagnostic sagepub.com/journals-permissions DOI: 10.1177/0300060519893837 and prognostic genes for journals.sagepub.com/home/imr lung adenocarcinoma and squamous cell carcinoma Xing Wu1,*, Linlin Wang2,*, Fan Feng3 and Suyan Tian4 Abstract Objective: To construct a diagnostic signature to distinguish lung adenocarcinoma from lung squamous cell carcinoma and a prognostic signature to predict the risk of death for patients with nonsmall-cell lung cancer, with satisfactory predictive performances, good stabilities, small sizes and meaningful biological implications. Methods: Pathway-based feature selection methods utilize pathway information as a priori to provide insightful clues on potential biomarkers from the biological perspective, and such incor- poration may be realized by adding weights to test statistics or gene expression values. In this study, weighted gene expression profiles were generated using the GeneRank method and then the LASSO method was used to identify discriminative and prognostic genes. Results: The five-gene diagnostic signature including keratin 5 (KRT5), mucin 1 (MUC1), trigger- ing receptor expressed on myeloid cells 1 (TREM1), complement C3 (C3) and transmembrane serine protease 2 (TMPRSS2) achieved a predictive error of 12.8% and a Generalized Brier Score of 0.108, while the five-gene prognostic signature including alcohol dehydrogenase 1C (class I), gamma polypeptide (ADH1C), alpha-2-glycoprotein 1, zinc-binding (AZGP1), clusterin (CLU), cyclin dependent kinase 1 (CDK1) and paternally expressed 10 (PEG10) obtained a log-rank P-value of 0.03 and a C-index of 0.622 on the test set.
    [Show full text]
  • Original Article Up-Regulated AZGP1 Promotes Proliferation, Migration and Invasion in Colorectal Cancer
    Int J Clin Exp Pathol 2017;10(3):2794-2803 www.ijcep.com /ISSN:1936-2625/IJCEP0044317 Original Article Up-regulated AZGP1 promotes proliferation, migration and invasion in colorectal cancer Shixu Lv*, Yinghao Wang*, Fan Yang, Lijun Xue, Siyang Dong, Xiaohua Zhang, Lechi Ye Department of Surgical Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China. *Equal contributors. Received November 14, 2016; Accepted January 6, 2017; Epub March 1, 2017; Published March 15, 2017 Abstract: Zinc-α-2-glycoprotein (AZGP1) is a multi-function protein, which has been detected in different malignan- cies. But the expression and function of AZGP1 in colorectal cancer is not clear. In this study, we explored the ex- pression and function of AZGP1 in colorectal cancer. We analyzed the Cancer Genome Atlas (TCGA) and found that AZGP1 gene in colorectal cancer was upregulated at the transcriptional level. Real-time quantitative PCR (qPCR) was performed to evaluate AZGP1 expression level in colorectal cancer specimens and normal mucosa speci- mens. The association between AZGP1 expression and clinicopathological factors was analyzed. We found that AZGP1 expression was positively associated with AJCC clinical stage, tumor invasion, and lymph node metastasis. In order to demonstrate the function of AZGP1, AZGP1-downregulation shRNA was constructed and subsequently stably transfected into HTC116 cells. We found that proliferation, migration and invasion were inhibited in AZGA1- downregulation HCT116 cell line, which is consistent with cell cycle blocked. Meanwhile, knockdown of AZGP1 promoted E-cadherin expression, which may induce invasion and migration. In conclusion, AZGP1 was an oncogene in colorectal cancer.
    [Show full text]
  • Prolactin-Induced Protein Mediates Cell Invasion and Regulates Integrin Signaling in Estrogen Receptor-Negative Breast Cancer Ali Naderi* and Michelle Meyer
    Naderi and Meyer Breast Cancer Research 2012, 14:R111 http://breast-cancer-research.com/content/14/4/R111 RESEARCHARTICLE Open Access Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer Ali Naderi* and Michelle Meyer Abstract Introduction: Molecular apocrine is a subtype of estrogen receptor (ER)-negative breast cancer that is characterized by a steroid-response gene signature. We have recently identified a positive feedback loop between androgen receptor (AR) and extracellular signal-regulated kinase (ERK) signaling in this subtype. In this study, we investigated the transcriptional regulation of molecular apocrine genes by the AR-ERK feedback loop. Methods: The transcriptional effects of AR and ERK inhibition on molecular apocrine genes were assessed in cell lines. The most regulated gene in this process, prolactin-induced protein (PIP), was further studied using immunohistochemistry of breast tumors and xenograft models. The transcriptional regulation of PIP was assessed by luciferase reporter assay and chromatin immunoprecipitation. The functional significance of PIP in cell invasion and viability was assessed using siRNA knockdown experiments and the mechanism of PIP effect on integrin-b1 signaling was studied using immunoblotting and immunoprecipitation. Results: We found that PIP is the most regulated molecular apocrine gene by the AR-ERK feedback loop and is overexpressed in ER-/AR+ breast tumors. In addition, PIP expression is regulated by AR-ERK signaling in xenograft models. These observations are explained by the fact that PIP is a target gene of the ERK-CREB1 pathway and is also induced by AR activation. Furthermore, we demonstrated that PIP has a significant functional role in maintaining cell invasion and viability of molecular apocrine cells because of a positive regulatory effect on the Integrin-ERK and Integrin-Akt signaling pathways.
    [Show full text]
  • AZGP1 Inhibits Soft Tissue Sarcoma Cells Invasion and Migration Jiayong Liu1, Haibo Han2, Zhengfu Fan1, Marc El Beaino3, Zhiwei Fang1, Shu Li1 and Jiafu Ji4,5*
    Liu et al. BMC Cancer (2018) 18:89 DOI 10.1186/s12885-017-3962-5 RESEARCHARTICLE Open Access AZGP1 inhibits soft tissue sarcoma cells invasion and migration Jiayong Liu1, Haibo Han2, Zhengfu Fan1, Marc El Beaino3, Zhiwei Fang1, Shu Li1 and Jiafu Ji4,5* Abstract Background: One of the major challenges in soft tissue sarcomas is to identify factors that predict metastasis. AZGP1 is a potential biomarker of cancer progression, but its value in soft tissue sarcomas remains unknown. The aim of this study is to determine the expression level of AZGP1 in soft tissue sarcomas, and to analyze its influence on tumor progression. Methods: AZGP1 immunohistochemistry (IHC) and RT-PCR were performed in 86 patients with soft tissue sarcomas. The relationships between AZGP1 levels and clinicopathologic features were analyzed. In vitro experiments were performed using fibrosarcoma (HT1080), rhabdomyosarcoma (RD) and synovial sarcoma (SW982) cell lines to corroborate our findings. We used lentiviral over-expression and knockdown assays to examine how changes of AZGP1 expressions might affect cellular migration and invasion. Results: ThequantitativeRT-PCRresultsshowedthatAZGP1expression was negatively correlated with metastasis and overall survival in soft tissue sarcomas (p < 0.05). Immunohistochemical staining showed lower expression of AZGP1 in patients with metastasis than in those without. Kaplan-Meier survival analysis showed that patients with low expression of AZGP1 had shorter overall (p = 0.056) and metastasis-free survivals (p =0.038).Thesefindings were corroborated by our in vitro experiments. Over-expression of AZGP1 significantly decreased RD cellular migration and invasion by 64% and 78%, respectively. HT1080 cells migration was inhibited by 2-fold, whereas their invasion was repressed by 7-fold after AZGP1 knockdown.
    [Show full text]
  • Secreted Indicators of Androgen Receptor Activity in Breast Cancer Pre-Clinical Models
    Secreted Indicators of Androgen Receptor Activity in Breast Cancer Pre-Clinical Models. Toru Hanamura ( [email protected] ) Tokai University School of Medicine https://orcid.org/0000-0002-6934-8588 Jessica L Christenson University of Colorado Denver - Anschutz Medical Campus: University of Colorado - Anschutz Medical Campus Kathleen I O’Neil University of Colorado Denver - Anschutz Medical Campus: University of Colorado - Anschutz Medical Campus Emmanuel Rosas University of Colorado Anschutz Medical Campus: University of Colorado - Anschutz Medical Campus Nicole S Spoelstra University of Colorado Anschutz Medical Campus: University of Colorado - Anschutz Medical Campus Michelle M Williams University of Colorado Anschutz Medical Campus: University of Colorado - Anschutz Medical Campus Jennifer K Richer University of Colorado Anschutz Medical Campus: University of Colorado - Anschutz Medical Campus Research article Keywords: breast cancer, androgen signal, androgen receptor, serum factor, KLK3, AZGP1, PIP, prostate specic antigen (PSA), zinc-alpha-2-glycoprotein (ZAG), prolactin induced protein (PIP) Posted Date: August 10th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-786707/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/26 Abstract Purpose. Accumulating evidence has attracted attention to the androgen receptor (AR) as a biomarker and therapeutic target in breast cancer. We hypothesized that AR activity within the tumor has clinical implications and investigated whether androgen responsive serum factors might serve as a minimally invasive indicator of tumor AR activity. Methods. Based on a comprehensive gene expression analysis of an AR-positive breast cancer patient- derived xenograft (PDX) model, 163 dihydrotestosterone (DHT)-responsive genes were dened as an androgen responsive gene set.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,371,528 B2 Stankovic Et Al
    US009371528B2 (12) United States Patent (10) Patent No.: US 9,371,528 B2 Stankovic et al. (45) Date of Patent: Jun. 21, 2016 (54) METHODS FORTREATING POLYPS NIH 3T3 Fibroblasts.” Molecular and Cellular Biology 14(7):4398 4407. (71) Applicant: Massachusetts Eye and Ear Infirmary, Allen et al. (1997) “Spinophilin, a novel protein phosphatase 1 bind Boston, MA (US) ing protein localized to dendritic spines.” Proc. Natl. Acad. Sci. USA 94:9956-9.961. (72) Inventors: Konstantina M. Stankovic, Boston, MA Anand et al. (2006) “Inflammatory pathway gene expression in (US); Ralph Metson, Newton, MA (US) chronic rhinosinusitis. Am. J. Rhinol. 20:471-476. Araki et al. (1988) “Complete amino acid sequence of human plasma (73) Assignee: Massachusetts Eye and Ear Infirmary, Zn-O-glycoprotein and its homology to histocompatibility anti Boston, MA (US) gens.” Proc. Natl. Acad. Sci. USA 85:679-683. Armstrong et al. (1997) “PPP1R6, a novel member of the family of (*) Notice: Subject to any disclaimer, the term of this glycogen-targetting Subunits of protein phosphatase 1.” FEBS Let patent is extended or adjusted under 35 ters 418:210-214. U.S.C. 154(b) by 0 days. Bahram et al. (1994) “A second lineage of mammalian major histocompatibility complex class I genes.” Proc. Natl. Acad. Sci. (21) Appl. No.: 14/179,510 USA 91: 6259-6263. Bao et al. (2004) “Periostin potently promotes metastatic growth of (22) Filed: Feb. 12, 2014 colon cancer by augmenting cell survival via the Akt/PKB pathway.” (65) Prior Publication Data Cancer Cell 5:329-339. Bao et al. (2005) "Zinc-O-glycoprotein, a lipid mobilizing factor, is US 2014/O255421 A1 Sep.
    [Show full text]
  • Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors
    University of Cincinnati Date: 12/20/2010 I, Arturo R Maldonado , hereby submit this original work as part of the requirements for the degree of Doctor of Philosophy in Developmental Biology. It is entitled: Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors Student's name: Arturo R Maldonado This work and its defense approved by: Committee chair: Jeffrey Whitsett Committee member: Timothy Crombleholme, MD Committee member: Dan Wiginton, PhD Committee member: Rhonda Cardin, PhD Committee member: Tim Cripe 1297 Last Printed:1/11/2011 Document Of Defense Form Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors A dissertation submitted to the Graduate School of the University of Cincinnati College of Medicine in partial fulfillment of the requirements for the degree of DOCTORATE OF PHILOSOPHY (PH.D.) in the Division of Molecular & Developmental Biology 2010 By Arturo Rafael Maldonado B.A., University of Miami, Coral Gables, Florida June 1993 M.D., New Jersey Medical School, Newark, New Jersey June 1999 Committee Chair: Jeffrey A. Whitsett, M.D. Advisor: Timothy M. Crombleholme, M.D. Timothy P. Cripe, M.D. Ph.D. Dan Wiginton, Ph.D. Rhonda D. Cardin, Ph.D. ABSTRACT Since 1999, cancer has surpassed heart disease as the number one cause of death in the US for people under the age of 85. Malignant Peripheral Nerve Sheath Tumor (MPNST), a common malignancy in patients with Neurofibromatosis, and colorectal cancer are midkine- producing tumors with high mortality rates. In vitro and preclinical xenograft models of MPNST were utilized in this dissertation to study the role of midkine (MDK), a tumor-specific gene over- expressed in these tumors and to test the efficacy of a MDK-transcriptionally targeted oncolytic HSV-1 (oHSV).
    [Show full text]
  • Review Article Prolactin-Induced Protein (PIP)-Characterization and Role in Breast Cancer Progression
    Am J Cancer Res 2018;8(11):2150-2164 www.ajcr.us /ISSN:2156-6976/ajcr0085184 Review Article Prolactin-induced protein (PIP)-characterization and role in breast cancer progression Anna Urbaniak1,2, Karolina Jablonska2, Marzenna Podhorska-Okolow2, Maciej Ugorski1,4, Piotr Dziegiel2,3 1Laboratory of Glycobiology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland; 2Department of Human Morphology, Division of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland; 3Department of Physiotherapy, University School of Physical Education, Wro- claw, Poland; 4Department of Biochemistry and Molecular Biology, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland Received September 7, 2018; Accepted September 17, 2018; Epub October 1, 2018; Published October 15, 2018 Abstract: Prolactin-induced protein (PIP) is a small secreted glycoprotein carrying several N-linked carbohydrate chains. The expression of PIP is generally restricted to cells with apocrine properties. It was found in apocrine glands of the axilla, vulva, eyelid, ear canal, and seminal vesicle. Being a secretory protein, PIP is present in seminal plasma, saliva, lacrimal fluid, tears, sweat gland secretion. Little is known about the biological role of PIP. It binds to numerous proteins, however, in most cases the biological role of such interactions is poorly understood. A notable exception is its binding to CD4 receptors present on the surface of T lymphocytes, macrophages, and spermatozoa. The available data suggest that PIP can have immunomodulatory functions and plays an important role in cell- mediate adoptive immunity. PIP binds to bacteria from several genera, which suggests that this glycoprotein may participate also in innate immunity and protection of hosts against microbial infections.
    [Show full text]